Glenmark’s molecule GRC 10693 to enter Phase I trials

Glenmark Pharmaceuticals Ltd. (GPL) today announced that its candidate for Neuropathic Pain, Osteoarthritis and other Inflammatory Pain – GRC 10693 is entering Phase I trials. The company intends to develop GRC 10693, a cannabinoid-2 [CB-2] receptor agonist, in neuropathic pain as the primary indication. The molecule has been filed for Phase 1 approval with European regulatory authorities. Glenmark expects to complete Phase I trials for GRC 10693 and initiate Phase II before the end of FY 09.

Speaking on this development, Mr. Glenn Saldanha, MD & CEO, Glenmark Pharmaceuticals Ltd. (GPL) said, “We are happy to take GRC 10693 forward into Phase I trials. This is Glenmark’s fifth molecule to enter the clinics from our pipeline of thirteen NCEs and NBEs, and is an affirmation of Glenmark’s research capabilities and focused approach towards drug discovery. This development reiterates Glenmark’s commitment towards setting new benchmarks in speed, efficacy and demonstrates the company’s steady progress in the drug discovery space.”  He further added “There has been significant scientific interest and commercial attention devoted to the cannabinoid receptors as potential pain targets with several pharma majors having active CB-2 programs. However, only a few molecules have progressed through to the clinical testing stages. In this context, we are glad to have a Phase I ready molecule that could present a potential opportunity as it matures. We see this as further validation of the strength and speed of our discovery program.” 

Sourced From: Glenmark Pharmaceuticals Ltd